Referências
Principais artigos
Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017 Feb;15(2):312-22.Texto completo Resumo
Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012 Aug;158(3):323-35.Texto completo Resumo
Terrell DR, Williams LA, Vesely SK, et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005 Jul;3(7):1432-6.Texto completo Resumo
Moschowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries. Arch Intern Med. 1925;36:89.
Moore JC, Hayward CP, Warkentin TE, et al. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood. 2001 Sep 15;98(6):1842-6.Texto completo Resumo
Banno F, Kokame K, Okuda T, et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood. 2006 Apr 15;107(8):3161-6.Texto completo Resumo
Veyradier A, Meyer D. Thrombotic thrombocytopenic purpura and its diagnosis. J Thromb Haemost. 2005 Nov;3(11):2420-7. Resumo
Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991 Aug 8;325(6):393-7. Resumo
Cuker A, Cataland SR, Coppo P, et al. Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021 Apr 8;137(14):1855-61.Texto completo Resumo
Artigos de referência
1. Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017 Feb;15(2):312-22.Texto completo Resumo
2. Vesely SK, George JN, Lammle B, et al. ADAMTS-13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60-68.Texto completo Resumo
3. Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020 Oct;18(10):2496-502.Texto completo Resumo
4. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012 Aug;158(3):323-35.Texto completo Resumo
5. Tehrani HA, Darnahal M, Vaezi M, et al. COVID-19 associated thrombotic thrombocytopenic purpura (TTP); a case series and mini-review. Int Immunopharmacol. 2021 Apr;93:107397. Resumo
6. Altowyan E, Alnujeidi O, Alhujilan A, et al. COVID-19 presenting as thrombotic thrombocytopenic purpura (TTP). BMJ Case Rep. 2020 Dec 17;13(12):e238026.Texto completo Resumo
7. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676-1687. Resumo
8. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267-1279.Texto completo Resumo
9. Yu J, Yuan X, Chen H, et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020 Oct 29;136(18):2080-9.Texto completo Resumo
10. Gavriilaki E, Brodsky RA. Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily. Br J Haematol. 2020 Jun;189(6):e227-e230.Texto completo Resumo
11. Chang JC, Kathula SK. Various clinical manifestations in patients with thrombotic microangiopathy. J Investig Med. 2002;50:201-206. Resumo
12. Wajima T, Johnson EH. Sudden cardiac death from TTP. Clin Appl Thromb Hemost. 2000;6:108-110. Resumo
13. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017 May 25;129(21):2836-46.Texto completo Resumo
14. Mariotte E, Azoulay E, Galicier L, et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016 May;3(5):e237-45.Texto completo Resumo
15. George JN, Al-Nouri ZL. Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematology Am Soc Hematol Educ Program. 2012;2012:604-9.Texto completo Resumo
16. Miller D, Kaye JA, Shea K, et al. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology. 2004;15:208-215. Resumo
17. Terrell DR, Williams LA, Vesely SK, et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005 Jul;3(7):1432-6.Texto completo Resumo
18. Sadler JE, Moake JL, Miyata T, et al. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2004;407-423.Texto completo Resumo
19. Swart L, Schapkaitz E, Mahlangu JN. Thrombotic thrombocytopenic purpura: A 5-year tertiary care centre experience. J Clin Apher. 2019 Feb;34(1):44-50. Resumo
20. Moschowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries. Arch Intern Med. 1925;36:89.
21. Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996 May 15;87(10):4223-34.Texto completo Resumo
22. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998 Nov 26;339(22):1585-94. Resumo
23. Bianchi V, Robles R, Alberio L, et al. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002 Jul 15;100(2):710-3.Texto completo Resumo
24. Moore JC, Hayward CP, Warkentin TE, et al. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood. 2001 Sep 15;98(6):1842-6.Texto completo Resumo
25. Banno F, Kokame K, Okuda T, et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood. 2006 Apr 15;107(8):3161-6.Texto completo Resumo
26. Crawley JT, Scully MA. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies. Hematology Am Soc Hematol Educ Program. 2013;2013:292-9. Resumo
27. Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008. Intern Med. 2010;49(1):7-15.Texto completo Resumo
28. Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res. 2011 Sep 15;17(18):5858-66. Resumo
29. Nicol KK, Shelton BJ, Knovich MA, et al. Overweight individuals are at increased risk for thrombotic thrombocytopenic purpura. Am J Hematol. 2003 Nov;74(3):170-4.Texto completo Resumo
30. McMinn JR, George JN. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. J Clin Apher. 2001;16(4):202-9. Resumo
31. Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol. 1989 Jun;7(6):781-9. Resumo
32. Page Y, Tardy B, Zeni F, et al. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet. 1991 Mar 30;337(8744):774-6. Resumo
33. Dzik WH, Georgi BA, Khettry U, et al. Cyclosporine-associated thrombotic thrombocytopenic purpura following liver transplantation - successful treatment with plasma exchange. Transplantation. 1987 Oct;44(4):570-2. Resumo
34. Meisenberg BR, Robinson WL, Mosley CA, et al. Thrombotic thrombocytopenic purpura in human immunodeficiency (HIV)-seropositive males. Am J Hematol. 1988 Mar;27(3):212-5. Resumo
35. Daly AS, Xenocostas A, Lipton JH. Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant. 2002 Dec;30(11):709-15.Texto completo Resumo
36. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000 Jun 15;342(24):1773-7. Resumo
37. Zakarija A, Kwaan HC, Moake JL, et al. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl. 2009 Feb;(112):S20-4. Resumo
38. Kojouri K, Vesely S, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med. 2001 Dec 18;135(12):1047-51. Resumo
39. Patton JF, Manning KR, Case D, et al. Serum lactate dehydrogenase and platelet count predict survival in thrombotic thrombocytopenic purpura. Am J Hematol. 1994 Oct;47(2):94-9. Resumo
40. Masias C, Cataland SR. The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis. Blood. 2018 Aug 30;132(9):903-10.Texto completo Resumo
41. Hubbard AR, Heath AB, Kremer Hovinga JA, et al. Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH. J Thromb Haemost. 2015 Jun;13(6):1151-3.Texto completo Resumo
42. Zheng XL, Wu HM, Shang D, et al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica. 2010 Sep;95(9):1555-62.Texto completo Resumo
43. Veyradier A, Meyer D. Thrombotic thrombocytopenic purpura and its diagnosis. J Thromb Haemost. 2005 Nov;3(11):2420-7. Resumo
44. Shih AW, McFarlane A, Verhovsek M. Haptoglobin testing in hemolysis: measurement and interpretation. Am J Hematol. 2014 Apr;89(4):443-7. Resumo
45. Francis KK, Kalyanam N, Terrell DR, et al. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases. Oncologist. 2007 Jan;12(1):11-9.Texto completo Resumo
46. Booth KK, Terrell DR, Vesely SK, et al. Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol. 2011 Sep;86(9):743-51. Resumo
47. Dold S, Singh R, Sarwar H, et al. Frequency of microangiopathic hemolytic anemia in patients with systemic lupus erythematosus exacerbation: distinction from thrombotic thrombocytopenic purpura, prognosis, and outcome. Arthritis Rheum. 2005 Dec 15;53(6):982-5.Texto completo Resumo
48. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006 May 4;354(18):1927-35. Resumo
49. Pereira A, Mazzara R, Monteagudo J, et al. Thrombotic thrombocytopenic purpura⁄hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol. 1995 Jun;70(6):319-23. Resumo
50. Michael M, Elliott EJ, Craig JC, et al. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009 Feb;53(2):259-72. Resumo
51. Michael M, Elliott EJ, Ridley GF, et al. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD003595.Texto completo Resumo
52. Brunskill SJ, Tusold A, Benjamin S, et al. A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Transfus Med. 2007 Feb;17(1):17-35. Resumo
53. Qu L, Kiss JE. Thrombotic microangiopathy in transplantation and malignancy. Semin Thromb Hemost. 2005 Dec;31(6):691-9. Resumo
54. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991 Aug 8;325(6):393-7. Resumo
55. Bell WR, Braine HG, Ness PM, et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991 Aug 8;325(6):398-403.Texto completo Resumo
56. Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019 Jan 9;380(4):335-46. Resumo
57. Cuker A, Cataland SR, Coppo P, et al. Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021 Apr 8;137(14):1855-61.Texto completo Resumo
58. Swisher KK, Terrell DR, Vesely SK, et al. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion. 2009 May;49(5):873-87. Resumo
59. Elliott MA, Heit JA, Pruthi RK, et al. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol. 2009 Oct;83(4):365-72. Resumo
60. Page EE, Kremer Hovinga JA, Terrell DR, et al. Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2016 Jun 16;127(24):3092-4.Texto completo Resumo
61. Owattanapanich W, Wongprasert C, Rotchanapanya W, et al. Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029618825309.Texto completo Resumo
62. Bobbio-Pallavivini E, Gugliotta L, Centurioni R, et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica. 1997 Jul-Aug;82(4):429-35.Texto completo Resumo
63. Welborn JL, Emrick P, Acevedo M. Rapid improvement of thrombotic thrombocytopenic purpura with vincristine and plasmapheresis. Am J Hematol. 1990 Sep;35(1):18-21. Resumo
64. O'Connor NT, Bruce-Jones P, Hill LF. Vincristine therapy for thrombotic thrombocytopenic purpura. Am J Hematol. 1992 Mar;39(3):234-6. Resumo
65. Bird JM, Cummins D, Machin SJ. Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpura. Lancet. 1990 Sep 1;336(8714):565-6. Resumo
66. Udvardy M, Rak K. Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpura. Lancet. 1990 Dec 15;336(8729):1508-9. Resumo
67. Strutz F, Wieneke U, Braess J, et al. Treatment of relapsing thrombotic thrombocytopenic purpura with cyclophosphamide pulse therapy. Nephrol Dial Transplant. 1998 May;13(5):1320-1.Texto completo Resumo
68. Pasquale D, Vidhya R, DaSilva K, et al. Chronic relapsing thrombotic thrombocytopenic purpura: role of therapy with cyclosporine. Am J Hematol. 1998 Jan;57(1):57-61.Texto completo Resumo
69. van Ojik H, Biesma DW, Fijnheer R, et al. Cyclosporine for thrombotic thrombocytopenic purpura after autologous bone marrow transplantation. Br J Haematol. 1997 Mar;96(3):641-3. Resumo
70. Outshoorn UM, Ferber A. Outcomes in the treatment of thrombotic thrombocytopenic purpura with splenectomy: a retrospective cohort study. Am J Hematol. 2006 Dec;81(12):895-900. Resumo
71. Dubois L, Gray DK. Case series: splenectomy: does it still play a role in the management of thrombotic thrombocytopenic purpura? Can J Surg. 2010 Oct;53(5):349-55.Texto completo Resumo
72. Mori Y, Wada H, Gabazza EC, et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion. 2002;42:572-580. Resumo
73. Zheng XL, Kaufman RM, Goodnough LT, et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103:4043-4049.Texto completo Resumo
74. Coppo P, Wolf M, Veyradier A, et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol. 2006;132:66. Resumo
75. Patschan D, Witzke O, Durhsen U, et al. Acute myocardial infarction in thrombotic microangiopathies - clinical characteristics, risk factors, and outcome. Nephrol Dial Transplant. 2006 Jun;21(6):1549-54.Texto completo Resumo
76. Howard MA, Williams LA, Terrell DR, et al. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion. 2006 Jan;46(1):154-6. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal